Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | TP53 | P04637 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17609554 | 0.86 | MAPT (0.52) | MAPTTP53SMN1; SMN2GAAMEN1 | |
| SCHEMBL30302016 | 0.85 | MAPT (0.60) | MAPTTP53SMN1; SMN2POLBKDM4E | |
| SCHEMBL17609780 | 0.83 | MAPT (0.49) | MAPTTP53SMN1; SMN2GAAMEN1 | |
| SCHEMBL21861606 | 0.80 | MAPT (0.47) | MAPTTP53SMN1; SMN2GAAMEN1 | |
| SCHEMBL21861737 | 0.77 | MAPT (0.45) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL21861343 | 0.77 | MAPT (0.45) | MAPTTP53SMN1; SMN2GAAMEN1 | |
| SCHEMBL11907279 | 0.77 | MAPT (0.46) | MAPTTP53SMN1; SMN2GAAMEN1 | |
| SCHEMBL31349645 | 0.74 | MAPT (0.63) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2576436 | 0.71 | ACHE (0.48) | MAPTTP53SMN1; SMN2GAAMEN1 | |
| SCHEMBL15001406 | 0.69 | GPR39 (0.39) | MEN1KMT2AKDM4ECYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193880-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3193880-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2019-10-31 | — | — | US | disclosed |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2019-10-31 | — | — | US | disclosed |
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | HYDRA BIOSCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | HYDRA BIOSCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPV1, TRPA1, TRPV2 | MAPT 2292/4885TP53 4509/4885SMN1; SMN2 905/4885 |
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPV1, TRPA1, TRPV2 | MAPT 2292/4885TP53 4509/4885SMN1; SMN2 905/4885 |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MAPT 4106/4885TP53 59/4885SMN1; SMN2 2557/4885 |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPV1, TRPA1, TRPV2 | MAPT 2292/4885TP53 4509/4885SMN1; SMN2 905/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MAPT 4106/4885TP53 59/4885SMN1; SMN2 2557/4885 |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPV1, TRPA1, TRPV2 | MAPT 2292/4885TP53 4509/4885SMN1; SMN2 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.